Sherif A. Eldirany

Sherif A. Eldirany

Auto-generated profile, based on publicly available information

Sherif A. Eldirany

Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2024 in JID Innovations
Verified
Journal Article
Open access
SDStefano G. Daniele
Stefano G. Daniele
SESherif A. Eldirany
Sherif A. Eldirany
Giovanni DamianiGiovanni Damiani
Giovanni Damiani
MHMinh Ho
Minh Ho
Christopher G BunickChristopher G Bunick
Christopher G Bunick
IL-23 is central to psoriasis pathogenesis. Biologics targeting IL-23 are important therapies against psoriasis. IL-23 inhibitors risankizumab, tildrakizumab, and guselkumab bind the IL-23 p19 subunit, whereas ustekinumab binds p40; however, the structural composition of the IL-23–binding epitopes and how these molecular properties relate to clinical efficacy are not known. Utilizing epitope data derived from hydrogen-deuterium exchange or crystallographic experiments, we mapped inhibitor epitope locations, hydrophobicity, and surface charge onto the IL-23 surface. Molecular properties of each inhibitor epitope, including solvent-accessible surface area, were correlated to binding affinity, kinetic values, and clinical efficacy scores for plaque psoriasis through linear regression analysis. Each IL-23 inhibitor binds an epitope with a unique size, composition, and location except for a 10-residue overlap region outside of the IL-23 receptor epitope. We observed strong correlations between epitope surface area and KD and koff but not kon. Epitope surface area, KD, and koff were further associated with short-term (10–16 weeks) and long-term (44–60 weeks) clinical efficacy according to PASI-90 responses, with risankizumab demonstrating highest efficacy among IL-23 biologics. In contrast, kon, epitope hydrophobicity, polarity, and charge content did not correlate with efficacy. These data exemplify how molecular principles of medications within a therapeutic class can explain their differential clinical responses.

1 December 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
TWTiffany T. Wu
Tiffany T. Wu
SESherif A. Eldirany
Sherif A. Eldirany
Christopher G BunickChristopher G Bunick
Christopher G Bunick
JTJoyce Teng
Joyce Teng